Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Randomized Control Trial in Children With Moderate to Severe Atopic Dermatitis to Assess the Benefit of a Nurse-led One-to-one Education Program in Addition to Standard Care Compared to Standard Care Alone on the Long Term Control of Disease Severity at 6 Months

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with AD, defined according to the criteria of the United Kingdom Working Party : AD should be diagnosed when a child has an itchy skin condition plus three or more of the following: Protocol EDU DA RC15_0035 Version n°4 du 15/09/16 Page 28 sur 44 CONFIDENTIAL Visible flexural dermatitis involving the skin creases, such as the bends of the elbows or behind the knees (or visible dermatitis on the cheeks and/or extensor areas in children aged under 10 years) Personal history of flexural dermatitis (or dermatitis on the cheeks and/or extensor areas in children under 10 years) Personal history of dry skin in the last 12 months Personal history of asthma or allergic rhinitis (or history of atopic disease in a firstdegree relative of children aged under 4 years)~* Onset of signs and symptoms under the age of 2 years (this criterion should not be used in children aged less than 4 years). Patient aged at least 3 months and less than 18 years.~* SCORAD 20 (moderate to severe AD)~* Patient who received treatment an anti-inflammatory topical treatment (topical corticosteroid or topical tacrolimus)~* Informed consent of parents~* Agreement of the child when appropriate~* Patient affiliated to French social security system~Exclusion Criteria:~* Patient does not meet the criteria of AD~* SCORAD \< 20~* Patient aged 18 years or more~* Patient treated with oral corticosteroids currently or systemic immunosuppressant 2 months prior to the eligibility assessment~* Patients with primary immunodeficiency diseases.~* Consent not given~* Patient not affiliated to French social security system~* Patient with intercurrent disease, may be excluded if the investigator believes participation in the trial is not in the best interest of the patient~* Personal decision of the child or their parents not to be included~* Child and / or parents lack the mental capacity to give informed consent~* Child / Parents do not have a sufficient command of the French language for understanding TPE program.~* Patient or parent who has already received structured TPE for AD.

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Individual session therapeutic education (Type: EXPERIMENTAL): The children included in the active arm will undergo, along with their parents (by child's age and wish), a structured individual TPE session between W0 and W2. This session will be conducted by the nurse trained in TPE. The session will be one hour long.
- Control (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues